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Abstract: Identifying cancer drivers and actionable mutations is critical for precision oncology. In 
epithelial ovarian cancer (EOC) the majority of mutations lack biological or clinical validation. We 
fully characterized 43 lines of Patient-Derived Xenografts (PDXs) and performed copy number 
analysis and whole exome sequencing of 12 lines derived from naïve, high grade EOCs. 
Pyrosequencing allowed quantifying mutations in the source tumours. Drug response was assayed 
on PDX Derived Tumour Cells (PDTCs) and in vivo on PDXs. We identified a PIK3R1W624R variant 
in PDXs from a high grade serous EOC. Allele frequencies of PIK3R1W624R in all the passaged PDXs 
and in samples of the source tumour suggested that it was truncal and thus possibly a driver 
mutation. After inconclusive results in silico analyses, PDTCs and PDXs allowed the showing 
actionability of PIK3R1W624R and addiction of PIK3R1W624R carrying cells to inhibitors of the 
PI3K/AKT/mTOR pathway. It is noteworthy that PIK3R1 encodes the p85α regulatory subunit of 
PI3K, that is very rarely mutated in EOC. The PIK3R1W624R mutation is located in the cSH2 domain 
of the p85α that has never been involved in oncogenesis. These data show that patient-derived 
models are irreplaceable in their role of unveiling unpredicted driver and actionable variants in 
advanced ovarian cancer. 
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1. Introduction 
Epithelial Ovarian Cancer (EOC) is a heterogeneous disease with five major histologic types [1]. 
The most frequent is high grade serous EOC (HGS-EOC), characterized by disruption of TP53 [2]. 
The majority of patients with HGS-EOC present with advanced stage disease and there has been little 
improvement in overall survival with standard treatment, which has not changed over the past 20 
years and relies on cytoreductive surgery and platinum-based combination chemotherapy [3]. 
Maintenance therapy with inhibitors of the Poly (ADP-ribose) polymerase (PARP) now offers 
significant survival advantages for patients with BRCA1 and BRCA2 mutations [4,5], but targeted 
therapy for other HGS-EOC patients is much less developed compared to other solid tumours. In 
melanoma and non-small cell lung carcinomas, specific genetic alterations have been identified as 
key oncogenic drivers, i.e., as mutations able to confer a selective advantage to a cell, through either 
increasing its survival or proliferation and, thus, able to cause clonal expansion of the carrier cell. 
These findings have led to the development of therapies targeting these mutations, which has 
provided demonstrable clinical benefit [6]. Thus, a number of these mutations have also been defined 
as “actionable”, not only because their functional outcome makes carrier cells responsive to a targeted 
therapy, but also thanks to the availability of a specific targeted drug. 
In ovarian cancer, a handful of aberrations in cancer genes have been found at high frequency, 
but many more cancer-related genes are found mutated at a very low frequency (≈1%) [7,8]. This so-
called “long-tail” of candidate driver mutations [9] is still incompletely characterized not only in 
ovarian cancer but also across other human cancers [10]. Many of these mutations are not even well 
characterized oncogenic drivers [7,8] and evidence of the potential clinical impact is lacking. 
Thus, the goal of this study is to identify driver and therapeutically actionable molecular 
alterations in ovarian cancer. Primarily, with this purpose in mind, we [11] and other groups [12–18] 
have developed platforms of Patient-Derived Xenografts (PDXs) of EOC that can recapitulate the 
tumour biology and clinical responses observed in donor patients. PDXs provide the most conclusive 
tool to validate low frequency mutations as biomarkers for targeted therapy, as evidenced by the use 
of colorectal cancer PDX models to predict successful clinical trials [19]. 
Using PDX and PDX Derived Tumour Cells (PDTC), we provide here the identification and the 
detailed functional and therapeutic validation of a PIK3R1W624R mutation found in HGS-EOC. In HGS-
EOC point, mutations of genes encoding proteins of the PI3K-AKT-mTOR signalling pathway are 
very rare, whereas this pathway is very frequently affected by large genetic aberrations. The 
importance of this pathway in this and other cancer histotypes has prompted the clinical 
development of >40 different inhibitors [20]. However, we show here that although rare, the 
PIK3R1W624R is likely important, because it is identified as a truncal mutation in both the PDX line and 
source tumour. Thus, the PDX model has been instrumental in propelling the analysis, precisely 
because the genomic evolution of the source tumour grown in the immunodeficient animal model 
[21] did not counter-select this mutation. Moreover, we show here that the PDX model has been 
invaluable for functional validation, as it allowed overcoming questionable assays in test tubes or in 
unrelated cell types. 
2. Materials and Methods 
2.1. Cell Lines 
The OVCAR-8 (NCI-DTP Cat# OVCAR-8) were obtained from the NCI-DCTD repository. The 
A2780 (NCI-DTP Cat# A2780) ovarian carcinoma cells lines and the LNCaP prostate carcinoma cell 
line (CLS Cat# 300265/p761_LNCaP) were purchased from American Type Culture Collection 
(ATCC,). Cell cultures were maintained following the protocols suggested by the providers. 
2.2. Patient-Derived Xenograft (PDX) Platform 
Between 2012 and 2016, a collection of 167 separate clinical samples of epithelial ovarian cancers 
was undertaken, with the understanding and written consent of each subject before they participated 
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in the study, and according to the PROFILING Protocol, and it also conformed to the standards set 
by the Declaration of Helsinki, and was approved by the Regione Piemonte Ethical Committee 
(approval number 5141 on 9/3/2011), and then by the IRCCS Ethical Committee (approval number 
192/2016 on 19/7/2016). 
Samples have been implanted intra-peritoneum and subcutaneously in the right flank of 
severely immunocompromised NOD/Shi-scid/IL-2R γnull mice and subsequently propagated 
subcutaneously, based on our and other authors’ data showing that the continued development of 
the PDX model subcutis was suitable [11,12]. Sample quality was assessed by the pathologists. A total 
of 65 PDX lines successfully grew (thus with an approximate take of 40%) and were propagated for 
at least three passages. Table S1 shows the full characterization of tumours and a quality assurance 
of 43/65 PDX lines, carried out in accordance with Meehan et al. [22] within the first three passages 
of PDX lines, which resulted in loss of human stroma. For treatment, animals were randomized using 
the Laboratory Assistant Suite [23]. Animal treatment was initiated when mean xenograft volume 
was approximately 100 mm3. Buparlisib diluted in N-Methyl-2-pyrrolidone and PEG 10/90 v/v was 
administered by oral gavage every day 5 days/week for 3 weeks. Buparlisib was administered at the 
dose of 20 mg/kg, that was reported to be effective in diverse PDX models [24]. Treatment with 
buparlisib at doses >30 mg/kg resulted in mouse toxicity. Control animals were treated with vehicle 
alone. All animal procedures were approved by the local Ethical Commission and by the Italian 
Ministry of Health in accordance with EU Directive 2010/63/EU for animal experiments; a first 
authorization was obtained on 12/7/2012 and, following subsequent regulations, approved again on 
14/01/2016 (no. 16/2016-PR) and extended for two additional years on 17/9/2018. All animal 
procedures comply with the “3R” principles. Additional methodological details of animal 
experimentation are reported in Supplementary Methods Part 1. The completed ARRIVE guideline 
checklist for reporting experiments using live animals is attached as Supplementary Methods Part 2. 
2.3. TMAs and IHC 
Tissue Microarray (TMA) preparations and staining were carried out as described by Sapino et 
al. [25] TMA slides for the characterization of the PDX lines were stained with the Ventana automated 
immunostainer (BenchMark AutoStainer, Ventana Medical Systems, Tucson, AZ, USA) using the 
following antibodies by Ventana Medical Systems: anti-WT1 Cat# 760-4397, anti-p53 Cat# 790-2912, 
anti-EPCAM Cat# 760-4383, anti-Cytokeratin 7 Cat# 790-4462 and anti-CD20 Cat# 760-2531, the latter 
to rule out the growth of lymphoma, which occurred in 10–20% of cases, as also reported by others 
[26]. Immunohistochemical detection of S6 and P-S6 in TMA slides of PDXs was carried out using 
rabbit monoclonal antibodies (Cell Signalling Technology; Denvers, MA, USA) Cat# 2217 and Cat# 
4858, respectively, and anti-rabbit Ig (K4003) and EnVision system purchased from Dako (Agilent, 
Santa Clara, CA, USA). The immunohistochemical detection of Ki67 and P-S6 in sections of PDXs was 
carried out using mouse monoclonal (Dako clone MIB-1) and rabbit monoclonal antibodies (Cell 
Signalling Technology Cat# 4858) respectively, anti-mouse or anti-rabbit Ig (K4001 and K4003, 
respectively) and EnVision system purchased from Dako (Agilent, Santa Clara, CA, USA). 
Quantification of P-S6 and Ki67 positive cells was carried out using the Colour Deconvolution plug-
in in ImageJ in 20–30 and 10–15 separated fields, respectively, of each PDX. 
2.4. PDX Derived Tumour Cell (PDTC) Preparation 
PDX samples have been chopped and digested with a Human Tumour Dissociation Kit (Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to the manufacturer protocol. Human cells were 
isolated using a Mouse Cell Depletion Kit (Miltenyi Biotec). Cells were plated, and after 24–48 h 
treated with a drug in 96-multiwell plates. 
2.5. Viability and Cytotoxicity Assays 
A CellTiter-Glo® assay was used to evaluate the viability of PDTCs and cell lines after 72 h 
treatment with drugs, according to the manufacturer’s protocol (Promega, Madison, WI, USA). Drugs 
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were purchased from Selleck Chemicals (Houston, TX, USA). GR values have been calculated for 
each concentration as reported in Hafner et al. [27] and plotted using a GraphPad Prism version 7.02 
(San Diego, CA, USA). 
A c ytotoxicity assay was carried out as follows. Seventy-two hours after treatment, cells in 96-
well plates were fixed with 2% paraformaldehyde in PBS for 40 min, washed twice in PBS and stained 
with 10% crystal violet in 20% methanol for 40 min. Plates were washed extensively and lysed in 10% 
acetic acid. The absorbance was measured at 595 nm using a microplate reader (BioTek Synergy HTX, 
Winooski, VT, USA). 
2.6. Western Blot Analysis 
PDTCs were treated for 24 h with the indicated drug or the vehicle 24 h after plating. From 
PDTCs and PDX samples, proteins were extracted in ice cold elution buffer (TrisHCl pH 7.4, 
containing EDTA, 1% Triton X-100, 10% glycerol and protease and phosphatase inhibitors). Proteins 
of snap frozen PDXs have been extracted as above after GentleMacs (Miltenyi Biotec) digestion. 
Western blot (WB) analysis was carried using the following antibodies: rabbit polyclonal anti-AKT 
(Cell Signalling Technology Cat# 9272), rabbit monoclonal Phospho(Ser473)-AKT (Cell Signaling 
Technology Cat# 4060) and polyclonal goat anti-vinculin (N-19) (Santa Cruz Biotechnology Cat# sc-
7649). Labelled secondary antibodies have been revealed with ECL (Thermo Fisher Scientific, 
Waltham, MA, USA) using the ChemiDoc Touch Imaging System (BioRad, Hercules, CA, USA). 
2.7. Crystal Structure Analysis 
The position of W624 residue in the structure of human p85α encoded by PIK3R1 was predicted 
through sequence alignments and structure superimposition. Sequence alignments and domain 
assignment were performed using PSI-Blast (NCBI BLAST), whereas structure superimposition was 
performed using UCSF Chimera. 
2.8. WES and CNA Analysis 
Exome library preparation was performed using the Nextera Rapid Capture Enrichment kit 
from Illumina. Genomic DNAs were quantified using the Qubit system (Invitrogen, Carlsbad, CA, 
USA) and 50 ng were used as input material for library preparation. Pools of 12-plex libraries (500 ng 
each library) were hybridized with capture probes (coding exomes oligos) twice: a first hybridization 
step for 2 h and a second for 18 h. After elution and clean up, enriched DNA libraries were amplified 
with 10-cycle PCR. The products were purified, loaded on a bioanalyser using DNA 1000 chip for 
quality control and quantified with Qubit. Samples were sequenced using the NextSeq 500 platform 
(Illumina, San Diego, CA, USA) as paired 150 bp reads, using the NextSeq 500/550 High Output Kit 
v2, loading 1.4 pM DNA and obtaining as cluster density an average of 200 K/mm2 clusters. 
Microarray HumanCytoSNP for CNA analysis was performed by Genomix4life S.R.L. (Baronissi, 
Salerno, Italy), using 200 ng of each DNA hybridized for 18 h at 48 °C on HumanCytoSNP-12 v2.1 
BeadChip, according to the manufacturer’s instructions, and analysed with an Illumina iSCAN. WES 
and SNP data analyses were performed using the pipeline shown in Figure S1, using each patient’s 
germline DNA as reference. The data generated or analysed during this study are included in this 
article, or if absent, are available from the corresponding author upon reasonable request. 
2.9. Pyrosequencing Analysis 
The presence and allele frequency of TP53 and PIK3R1 mutations in source tumours of any PDX 
line were assessed using pyrosequencing (QIAGEN, Hilden, Germany). Briefly, sample DNAs were 
amplified, and the PCR products were subjected to the ‘sequence by synthesis’ pyrosequencing 
method following the manufacturer’s instructions, using the primers and conditions reported in 
Table S5. Results were analysed with the PSQ24 software for allelic quantification. 
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3. Results 
3.1. Mutational Burden of PDX Lines from HGS-EOCs 
Forty-three PDX lines derived from epithelial ovarian carcinomas were fully characterized 
according to the minimal information standard for reporting PDX data [22], including clinical and 
pathological attributes of the patient’s tumour, the processes of implantation and passaging in the 
host mouse strain, and quality assurance by means of genotypic and phenotypic characterization. 
The information is reported in Table S1. Briefly, we compared the histology of each PDX to that of 
the source tumour and classified histotype using immunohistochemistry (IHC) with CK7, EPCAM, 
WT1 and p53 antibodies, which confirmed the diagnosis of high grade serous histology in 25/43 lines. 
Figure 1 shows the histology and IHC staining of TMAs of representative PDX lines and the 
corresponding source tumours. Targeted NGS of TP53 showed that all the PDXs from HGS-EOC 
harboured TP53 mutations (Table S1). TP53 aberrations were protein truncating or missense 
mutations previously shown to be pathogenic according to the IARC TP53 Database 
(http://p53.iarc.fr/). The detailed list of aberrations is reported in Table S1. Samples with missense 
mutations in TP53 had evidence of nuclear p53 stabilization as indicated by high protein expression 
in tumours and xenografts (Table S1). The PDX line with null splice site mutation did not express p53 
protein. The targeted NGS of BRCA1/2 showed mutations of these genes classified as likely 
pathogenic according to the BRCA Mutation Database (http://arup.utah.edu/database/BRCA) in 19% 
of the above PDX lines, i.e., close to the expected frequency. The likely impactful aberrations and the 
variants of unknown significance detected in the 43 PDX lines are listed in Table S1. 
 
Figure 1. Histological characterization of PDX lines. Representative images of TMAs of PDX lines 
compared to sections of the corresponding source tumours. Numbers on the left are those of PDX 
lines as catalogued by the PROFILING approved protocol, while the numbers of the used FFPE block 
of samples of source tumours are shown on the top left of each panel. The complete characterization 
of these and the other thirty-eight PDX lines is reported in Table S1. 
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We then further studied 12 PDX lines propagated from treatment naïve HGS-EOCs, listed in 
Table S2, that also reports clinical information. 
In the 12 PDX lines, using Whole Exome Sequencing (WES), we detected a total of 2743 single 
nucleotide variants (SNVs) in 2314 genes. The majority (79%) of mutated genes in our analysis have 
been reported as mutated in the TCGA analysis of 523 HGS-EOC [8]. Most (438/487) of the mutated 
genes not listed in the TCGA analyses of HGS-EOC have been found mutated in other cancer 
histotypes, according to the Pan-Cancer Atlas. 
TP53 was the only gene mutated in all 12 PDX lines, and the only gene found mutated across 
more than one PDX line (Table S1), with an allele frequency of approximately = 1, in line with 
occurrence of LOH. As expected, in the studied 12 PDX lines, WES detected the same TP53 mutations 
identified with targeted NGS. 
3.2. Somatic PIK3R1W624R Mutation in HGS-EOC 
To identify possible driver and actionable genetic aberrations in the 12 above-mentioned PDX 
lines, we considered SNVs and copy number alterations (CNAs) affecting cancer-related genes 
reported in COSMIC (CGCv84) [28]. 
CNAs detected in cancer genes corresponded to those reported in TCGA for HGS-EOC (Table 
S3A). Among genes reported in TCGA as amplified in more than 10% of cases [29], in our small series 
(Table S3B) we found the expected frequency of increased copy number of CCNE1 and PIK3CA. LOH 
of the TP53 gene in each of the PDX lines was confirmed (compare the data of Table S1 and Table S2). 
The list of cancer genes harbouring SNVs in the 12 PDX lines is shown in Figure 2 and Table S4. 
It came out that, in 3/12 PDX lines, WES did not detect mutations in known cancer genes other 
than TP53. A number of SNVs in cancer genes were identified as Single Nucleotide Polymorphisms 
(SNPs). All the variants are listed in Table S4. Only some of the somatic mutations in the remaining 
9 PDX lines were predicted to be damaging and/or deleterious based on the bioinformatics tools used 
for analysis (Figure 2, SIFT, PROVEAN and FATHMM [30]). Possible actionability (Figure 2) was 
evaluated using the Drug Gene interaction database (DGidb) [31]. 
In the PDX line #475, we found a point mutation of the PIK3R1 gene that results in the W624R 
residue substitution in the encoded protein. This was detected with an allele frequency 
approximately = 1.0, which suggested that this was a loss of function mutation followed by LOH, in 
accordance with PIK3R1 classification as a tumour suppressor gene. As explained above, based on 
the bioinformatic tools (see Figure 2), this mutation was predicted to be deleterious and damaging 
and possibly actionable. PIK3R1 encodes the p85α regulatory subunit of the p110α catalytic subunit 
of the Phosphatidyl-Inositol-3 Kinase (PI3K). Some of the already known mutations of the p85α 
subunit affect the intracellular signalling of the PI3K pathway, leading to PI3K activation, via distinct 
molecular mechanisms [32]. Activation of the PI3K pathway in this PDX line #475 was shown by the 
immunohistochemical detection of the phosphorylation of the S6 protein, that is a proxy of AKT 
activation (Figure S2). In other PDX lines, without mutations of genes involved in the 
PI3K/AKT/mTOR pathway, the P-S6 protein is not comparably increased (Figure S2). 
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Figure 2. Single Nucleotide Variants (SNVs) in cancer genes found in PDX lines derived from naïve 
HGS-EOC. Variants with an allele frequency (AF) ≥ 0.1 are listed. Only SNVs not classified as SNPs 
based on the SNP database are shown in this Figure 2. All the variants, including those classified as 
SNPs, are reported in the related Table S4. Legend to boxes is shown on the right. 
PIK3R1W624R was detected in all the parallel and sequential passages of the PDX line #475 and in 
each passage with an allele frequency approximately = 1.0. In these passages also, the same TP53 
mutation was found with an allele frequency approximately = 1.0, in line with TP53 mutation being 
a truncal mutation, as previously shown (see e.g., ref. [33]). Thus, data suggested that the PIK3R1W624R 
might also be a truncal mutation in PDXs. Most other mutations were also consistently detected in 
all passages of this PDX line, whereas only a few were limited to a subset of passages. The list of 
public, shared and private mutations found in passages is shown in Figure 3A. The consistency of 
public SNVs in parallel and sequential passages demonstrated the genetic stability upon passages of 
the PDXs carrying the PIK3R1W624R mutation. 
The PIK3R1W624R PDX line was propagated from a biopsy sample taken at laparoscopy from a 
patient with a stage IIIc HGS-EOC. This PDX line responded as well as the patient to platinum-based 
chemotherapy. Indeed, the patient received neo-adjuvant platinum-based chemotherapy followed by 
surgery. Regrettably, the patient relapsed after six months and received a second platinum-based line 
that came out to be limitedly effective. At post-chemotherapy surgery, another sample was 
propagated as the PDX line, which no longer responded to carboplatin. In this paired PDX line the 
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PIK3R1W624R mutation was also found with an AF approximately = 1. More importantly, we found the 
same PIK3R1W624R mutation in specimens of the source tumour. Pyrosequencing of two distinct FFPE 
samples of the source tumour showed that in each FFPE sample the percentage of the PIK3R1W624R 
sequence was the same as that of the TP53 allele found mutated in the PDX line (panels B–E of Figure 
3). The percentage of the mutated TP53 allele was considered a reliable proxy of the percentage of 
tumour cells in the source tumour specimens. 
 
Figure 3. Identification of the PIK3R1W624R mutation as truncal mutation in parallel and serial passages 
of the PDX line #475 and in the corresponding source tumour. (A) The W624R mutation in PIK3R1 is 
one of several public mutations found in seven parallel and serial passages of the PDX line#475. (B–
E) Pyrosequencing analysis confirmed the presence of the TP53 and the PIK3R1 mutations found in 
the #475 PDX line in two FFPE samples from distinct blocks of the source tumour. The TP53 and the 
PIK3R1 mutated sequences showed the same allele frequency (AF) in each sample. The AF of the PDX 
line-specific TP53 mutation was considered as a proxy of the percentage of tumour cells in the human 
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tumour samples. (B) Sequence of PIK3R1 in Control Reference Genome; (C) percentage of PIK3R1W624R 
in FFPE sample A1 from the paraffin block 2998 of the source tumour; (D) percentage of PIK3R1W624R 
in FFPE sample A4 from the paraffin block 2304 of the source tumour; (E) percentage of mutated 
sequences of TP53 and PIK3R1 in the two above FFPE samples. 
3.3. Ex Vivo and In Vivo Assays of PIK3R1W624R Actionability 
As mentioned above, to estimate the therapeutic implications of any given mutation, we first 
used the Drug Gene interaction database (DGidb) [31] that suggested the actionability of PIK3R1W624R. 
Another resource, the DEPO database (Database of Evidence for Precision Oncology, http://depo-
dinglab.ddns.net/), that focuses on specific mutations for therapeutic projections, was not useful 
because it does not report hotspot regions of the PIK3R1 gene. However, we focused further attention 
on this mutation because of the potential actionability of a member of the PI3K-AKT-mTOR pathway. 
Hypothesis on the functional role of any given mutation can also be formulated based on crystal 
structures of the molecules and complex of interest. Thus, we investigated the possible role of the 
W624R mutation in the interaction between the p85 isoforms and p110 isoforms of PI3K (Figure 4). 
 
Figure 4. Crystal structures showing interaction of the p110 isoforms with the p85 isoforms in human 
and mouse PI3K. (A) Domain organization of p85α. (B) Available crystal structure (PDB ID 4L1B) of 
human p110α isoform with catalytic activity (grey) complexed with nSH2 (blue) and iSH2 (green) 
domains of human p85α; (C) available crystal structure (PDB ID 2Y3A) of mouse p110β in complex 
with iSH2 (green) and cSH2 (pink) domains of mouse p85β. (D) Alignment of the cSH2 domains of 
the human p85α and mouse p85β; homology is shown in the middle: W624 of the human p85α protein 
is conserved and corresponds to the W616 of the mouse p85β protein (red box in D). 
Regrettably, only the crystal structure of human p110α in complex with nSH2 and iSH2 domains 
of p85α is available (PDB ID 4L1B, Figure 4B). Hence, we explored the possible role of the amino-acid 
residue homologue to the W624 in mouse p85 being available in the crystal structure of mouse p110β 
isoform in complex with iSH2 and cSH2 domains of mouse p85β isoform (PDB ID 2Y3A, Figure 4C). 
Structure superimposition showed that mouse p85β shares common folds with the human p85α 
counterpart. Sequence alignments demonstrated that human p85α and mouse p85β display 73% 
homology and 59% identity, whereas human p110α and mouse p110β sequences have 57% homology 
and 40% identity. According to sequence alignment (Figure 4D), the W624 in the human p85α 
corresponds to W616 in the mouse cSH2 domain of p85β. These data analyses showed that the W616 
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in the cSH2 domain of mouse p85β is not involved in the interaction between murine p85β and p110β. 
Thus, the structure-based prediction was inconclusive. 
Thus, we carried out the functional assays (Figure 5) of the PIK3R1W624R in cells of the PIK3R1W624R 
carrying PDX line #475 ex vivo, by challenging the susceptibility to inhibitors of the PI3K/AKT/mTOR 
pathway that could be activated by suppression of the p85α regulatory subunit and fruitfully 
targeted for therapy. 
 
Figure 5. Response of PIK3R1W624R carrying PDTCs to inhibitors of the PI3K/AKT/mTOR pathway. In 
each experiment, control cell lines were assayed, too. (A, C, E, G): Dose-response curves in 
CellTiterGlo 72 h viability assays. Normalized growth rate (GR value) inhibition metrics of three 
replicate experiments is shown to take into account cell division rates. The sign of GR values relates 
directly to response phenotype: positive for partial growth inhibition, zero for complete cytostatic 
effect and negative for cytotoxicity. The x axis shows drug concentration on a log10 (Log) scale. (B, D, 
F, H): Western blot analysis of the phosphorylation of the AKT signal transducer in response to drugs, 
as a proxy of PI3K activation status. (A) The PIK3R1W624R PDTCs showed susceptibility to the pan-
class I PI3K inhibitor buparlisib (BKM120), comparable to that of the highly responsive A2780 cells; 
(C) the PIK3R1W624R PDTCs showed susceptibility to the dual PI3K/mTOR inhibitor dactolisib 
(BEZ235), comparable to that of the most sensitive (OVCAR-8) of the above cell lines; (E) the 
PIK3R1W624R PDTCs were also highly susceptible to the p110α specific PI3K inhibitor alpelisib 
(BYL719) as well as the A2780 cells; and (G) resistant to the p110β specific inhibitor GSK2636771 to 
which the LNCaP cells are exquisitely susceptible. 
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To test cell susceptibility to drugs ex vivo, we propagated the PDX Derived Tumour Cells 
(PDTCs) depleted of mouse cells as short-term cultures. Viability assays were carried out by exposing 
PDTCs to inhibitors for 72 h. The susceptibility of PIK3R1W624R PDTCs was compared to that of the 
control cell lines (Figure 5) and to that of the PDTCs derived from the #2085 PDX line (Figure S3). The 
latter PDTCs were propagated from a bona fide HGS-EOC, carrying mutations of the TP53 and 
BRCA2 genes (Table S1), but not of genes involved in the PI3K/AKT/mTOR pathway. The following 
cell lines were assayed as controls, selected based on mutation spectrum (Cancer Cell Line 
Encyclopedia, https://portals.broadinstitute.org/ccle) and susceptibility or resistance to any given 
drug: A2780 ovarian carcinoma cells, carrying PIK3CA activating mutation and PTEN loss that make 
them highly sensitive to the pan-class I PI3K inhibitor buparlisib (BKM120), to the p110α specific 
inhibitor alpelisib (BYL-719) and to the dual PI3K/mTOR inhibitor dactolisib (BEZ235); the OVCAR-
8 ovarian carcinoma cells with wild-type PIK3CA and TP53 gene mutation, but known to be 
susceptible to the dual PI3K/mTOR inhibitor dactolisib (BEZ235), as reported by the Genomic of Drug 
Sensitivity in Cancer Project (https://www.cancerrxgene.org/), and the PTEN-mutated LNCaP 
prostate carcinoma cells that are known to be exquisitely susceptible to the p110β specific inhibitor 
GSK2636771. To take into account cell division rates across the PDTCs and cell lines, growth rate 
inhibition metrics were used, i.e., GR-calculator [27]. 
The PIK3R1W624R #475 PDTCs but not the non-mutated #2085 PDTCs, were sensitive to the pan-
class I PI3K inhibitor buparlisib (BKM120) as shown in Figure 5 and Figure S3, respectively. Figure 5 
also shows the susceptibility of the PIK3R1W624R #475 PDTCs to the p110α specific inhibitor alpelisib 
(BYL-719), compared to control cell lines. Similarly, these #475 PDTCs showed susceptibility to the 
dual PI3K and mTOR inhibitors dactolisib (BEZ235). Conversely, the p110β selective inhibitor 
GSK2636771 did not affect the PIK3R1W624R PDTCs. The susceptibility of PIK3R1W624R PDTCs to the 
four inhibitors was confirmed with a cytotoxicity assay (Figure S4). In line with the results of viability 
assays, buparlisib, dactolisib and alpelisib, but not GSK2636771, affected AKT phosphorylation 
(Figure 5), that is a proxy of PI3K activation status. 
Moreover, in vivo buparlisib delayed the growth of the PIK3R1W624R PDXs (Figure 6A). As the 
total decrease of tumour volume could not allow proper estimation of possibly cytostatic agents, we 
demonstrated also the strong reduction of Ki67 positive, i.e. proliferating, cells in treated PDXs 
(Figure 7A,C). AKT phosphorylation was reduced in xenografts in line with growth delay by 
buparlisib treatment (Figure 6B). Accordingly, phosphorylation of the S6 protein, that is a proxy of 
the PI3K/AKT activation, was reduced (Figure 7B,D). 
 
Figure 6. In vivo response of the PIK3R1W624R PDXs to buparlisib. Randomized mice were divided into 
two cohorts and treated with 20 mg/kg buparlisib, administered as described in the Methods section. 
(A) Growth curves of treated (black solid lines) and control (green solid lines) animals. (B) Western 
blot analysis of the phosphorylation of the AKT signal transducer in response to drugs, as a proxy of 
PI3K activation status in response to drugs, in the individual treated (T2 and T3) and control (C1) 
PDXs indicated in panel (A). 
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Figure 7. Immunohistochemical detection of proliferation index and decreased activation of PI3K in 
PIK3R1W624R PDXs, treated with buparlisib as shown in Figure 6. (A) Representative images of Ki67 
positive cells detected in treated and control PDXs grown as shown in Figure 6 panel A; (B) 
representative images of P-S6 positive cells detected in treated and control PDXs grown as shown in 
Figure 6 panel A. (C) Quantification of Ki67 positive nuclei evaluated as a percentage of positive area 
versus total nuclei area. (D) Quantification of P-S6 positive cells evaluated as a percentage of positive 
area versus total area. The p value has been calculated using unpaired t-Student test. 
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4. Discussion 
We demonstrate here that a rare mutation in the PIK3R1 tumour suppressor gene [29] is 
actionable in HGS-EOC using validated patient-derived models of the disease. PIK3R1 is very 
frequently mutated in other cancer histotypes, with the notable exception of HGS-EOC [10], in 
particular in uterine carcinomas and carcinosarcomas, glioblastoma, breast and colorectal cancer. 
Most of the mutations reported so far are located in the iSH2 domain of the PIK3R1 encoded p85α, 
which is known to bind and regulate the p110α subunit of PI3K [32]. The PIK3R1W624R mutation 
described here is located in the cSH2 domain of the p85α. The same W624R amino acid change has 
been reported previously, but not characterized, in one colorectal cancer [34], while a W624C 
substitution has been reported in one non-small cell lung carcinoma (NSCLC) [35], and a nucleotide 
change in the same codon, leading to a non-sense mutation being found in one stomach cancer sample 
[36] and one endometrial carcinoma [37]. Other rare mutations in the cSH2 of the PIK3R1 gene are 
reported in COSMIC (https://cancer.sanger.ac.uk/cosmic) and TumorPortal 
(http://www.tumorportal.org). The function of a number of these mutations has been studied in test 
tubes (see e.g., ref. [38]) or in functional assays in cell line models with totally different genetic 
backgrounds (see e.g., refs. [39,40]). As a result, the potential oncogenicity of only two mutations in 
the p85α cSH2 domain has been proposed based on the promotion of survival and growth of Ba/F3, 
a murine interleukin-3 dependent pro-B cell line. On the other hand, in the cSH2 domain of the p85α, 
several germline mutations are located, which in heterozygosity cause SHORT syndrome [41]. This 
syndrome is characterised by developmental defects and is historically defined by its acronym: Short 
stature (S), Hyperextensibility of joints and/or inguinal Hernia (H), Ocular depression (O), Rieger 
abnormality (R) and Teething delay (T). Molecular studies have shown that PIK3R1 mutations 
associated with SHORT syndrome result in defects, and not in the activation of PI3K signalling 
[41,42]. 
Surprisingly, another mutation in the cSH2 domain (the R649W substitution) has been reported 
in both endometrial carcinoma and as a hotspot in four families affected by SHORT syndrome [42]. 
Therefore, although prediction algorithms allowed us to classify the W624R amino acid change in 
PIK3R1 as possibly deleterious and damaging the protein product, it was difficult to predict its actual 
impact on ovarian cancer. As structure-based approaches are more specific than sequence-based 
approaches at predicting driver mutations [40], we endeavoured to model the association in p85α 
between the W624R mutation and the p110α subunit, but available crystal structures did not help in 
defining the impact of the PIK3R1W624R on human PI3K function. It has also been postulated that the 
role of the cSH2 domain of the human p85α in oncogenesis relies on its interaction with and inhibition 
of the p110β isoform of the PI3K [43]. We disproved this hypothesis with functional assays ex vivo 
that showed directly the susceptibility in vitro of PIK3R1W624R PTDCs to the p110α specific inhibitor 
alpelisib but not to the p110β specific inhibitor. Susceptibility to pathway inhibition was confirmed 
by treating PDTCs with a dual PI3K/mTOR inhibitor and with the pan class I PI3K inhibitor 
buparlisib, which also inhibited the growth of PDXs in vivo. These data confirmed the requirement 
of proper functional assays for evaluating the driving oncogenic effect of any given mutation. 
Other observations suggest that the impact of any mutation as well as its actionability could be 
better studied in patient-derived models and in the actual tissue affected. Nowadays, the traditional 
system of anatomic cancer classification has been overcome by a classification system based on 
molecular alterations shared by tumours across diverse tissue types. This concept has led to the 
development of so-called basket or umbrella trials. However, exceptions that challenge this concept 
have also become apparent from such notable examples as the unpredictable clinical responses to a 
potent BRAF inhibitor across diverse malignancies, all expressing the same BRAF mutation [44]. 
Altogether, the data show that, to assess the function of mutant alleles, assays in patient-derived 
models of the relevant cancer, such as PDXs and short-term PDTCs, are extremely important. Long-
term cultures of patients’ samples [45] are useful for drug screening. Short-term monolayer cultures 
[46] and organoids [47] derived from patients’ biopsies have been shown as a valuable model for 
rapid drug testing and thus for co-clinical trials, but their application may be limited by the modest 
take and throughput, respectively. Thus, all the patient-derived experimental models should be 
Cells 2020, 9, 442 14 of 17 
 
considered complementary and not alternative, as every model system is imperfect and suitable in 
its own way. 
The validation of PIK3R1W624R as a biomarker of response to PI3K/AKT/mTOR pathway 
inhibitors exceeds the aim of this work. The PI3K-AKT-mTOR signalling pathway is one of the most 
frequently dysregulated ones in human cancers. More than 40 inhibitors of this pathway have 
reached various stages of clinical development, but only a few have been approved by FDA and EMA 
[48]. In clinical studies, inhibitors of the pathway have shown limited efficacy and/or manageability 
[20]. P110 isoform-specific inhibitors appear more promising in trials [49–51]. In ovarian cancer, gene 
abnormalities other than homologous recombination defects are even more difficult to pair with an 
approved or investigational drug [52]. 
5. Conclusions 
In the ovarian cancer field, suitable preclinical models such as PDXs are still invaluable for 
population-based studies, as they might better mimic the inter-tumour heterogeneity that is seen in 
patients and might be predictive of the clinical efficacy of targeted drugs. This model allowed us to 
identify a rare mutation in the PIK3R1 gene in a domain that was not expected to be involved in 
oncogenesis, and showing that this mutation makes ovarian cancer cells responsive to inhibitors of 
the PI3K/AKT/mTOR pathway. 
Supplementary Materials: The following are available online, Supplementary Methods Part 1: additional 
methodological details of animal experimentation, Supplementary Methods Part 2: completed ARRIVE 
checklist, Figure S1: Pipeline of WES and SNP data analyses, Figure S2: Expression of P-S6 as proxy of PI3K 
activation in PDX lines, Figure S3: Comparison between the response of the PIK3R1W624R carrying PDTCs and 
non-mutated PDTCs to the pan-class I PI3K inhibitor buparlisib, Figure S4 Cytostatic/cytotoxic effects of PI3K 
pathway inhibitors on PIK3R1W624R carrying PDTCs and control cell lines evaluated using crystal violet staining, 
Table S1: List and molecular characterization of 43 PDX lines propagated from EOC samples, Table S2: Clinical 
information of the patients who donated the 12 samples of HGS-EOC that were studies in-depth with WES and 
SNP arrays, Table S3: CNAs detected in cancer genes in the 12 PDX lines studied in depth compared to CNAs 
reported in TCGA analysis of HGS-EOC (A) comparison between CNAs found in the PDX lines and CNAs 
reported in TCGA for HGS-EOC (B) CNAs of the genes found amplified in more than 10% of the HGS-EOCs 
reported in TCGA, detected in the 12 PDX lines, Table S4: Single Nucleotide Variants (SNV) in cancer genes 
found in PDX lines derived from naïve HGS-EOC comprising those classified as SNPs, Table S5: Primers and 
conditions used for pyrosequencing samples of human source tumours of PDXs with PIK3R1W624R mutation. 
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